Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Alan Calvert.

Newcastle AuthorsTitleYearFull text
Professor Alan Calvert
Professor Ruth Plummer
Effect of erlotinib on CYP3A activity, evaluated in vitro and by dual probes in patients with cancer2014
Professor Ruth Plummer
Dr Evan Mulligan
Professor Nicola Curtin
Professor Alan Calvert
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation2013
Dr Jane Margetts
Dr Yvette Drew
Dr Peter Stephens
Professor Alan Calvert
Professor Ruth Plummer
et al.
Erratum to: Phase I study of PM00104 (Zalypsis (R)) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors (vol 31, pg 623, 2013 Doi: 10.1007/s10637-012-9843-5)2013
Professor Ruth Plummer
Professor Alan Calvert
Phase I-II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma2013
Professor Ruth Plummer
Professor Alan Calvert
Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas2011
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Mike Cole
Professor Ruth Plummer
et al.
Expression of methylthioadenosine phosphorylase (MTAP) in malignant pleural mesothelioma (MPM) and its implication for pemetrexed-based chemotherapy2010
Dr Peter Stephens
Professor Alan Calvert
Professor Ruth Plummer
Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors2010
Professor Alan Calvert
Professor Ruth Plummer
Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours2010
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Amy Quinn
Professor Alan Calvert
et al.
The role of folate receptor alpha (FR alpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy2010
Amy Quinn
Professor Alan Calvert
Professor John Lunec
A Monoclonal Antibody for Detection of Folylpolyglutamate Synthetase in Paraffin Embedded Tissues2009
Professor Alan Calvert
A randomised, double-blind, phase II study of two doses of pemetrexed in the treatment of platinum-resistant, epithelial ovarian or primary peritoneal cancer2009
Dr Joyce Nutt
Kieran O'Toole
Dr Fiona Black
Professor Ruth Plummer
Professor Alan Calvert
et al.
Expression of folate receptor alpha (FRa) in malignant pleural mesothelioma patients by immunohistochemistry: a clinico-pathological analysis2009
Professor Alan Calvert
Phase 0 clinical trials: Recommendations from the task force on methodology for the development of innovative cancer therapies2009
Professor Ruth Plummer
Melanie Griffin
Dr Sally Coulthard
Julieann Sludden
Professor Alan Calvert
et al.
Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors2009
Professor Alan Calvert
Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)2008
Professor Alan Calvert
Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)2008
Sarah Wilkinson
Dr Ali Kucukmetin
Dr Steven Darby
Vincent Gnanapragasam
Professor Alan Calvert
et al.
Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancer2008
Professor Ruth Plummer
Professor Alan Calvert
Mechanisms of chemoresistance to alkylating agents in malignant glioma.2008
Professor Ruth Plummer
Professor Alan Calvert
Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery)2008
Professor Alan Calvert
Professor Ruth Plummer
Professor Nicola Curtin
Professor Richard Edmondson
Dr Yvette Drew
et al.
PARP inhibitors in cancer treatment2008
Professor Alan Calvert
Professor Nicola Curtin
Professor Ruth Plummer
PARP inhibitors in ovarian cancer2008
Professor Ruth Plummer
Professor Alan Calvert
Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors or lymphoma2008
Professor Ruth Plummer
Dr Christopher Jones
Professor Nicola Curtin
Professor Alan Boddy
Professor Herbie Newell
et al.
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors2008
Professor Alan Calvert
Professor Ruth Plummer
The Development of Phase I Cancer Trial Methodologies: the Use of Pharmacokinetic and Pharmacodynamic End Points Sets the Scene for Phase 0 Cancer Clinical Trials2008
Dr Yvette Drew
Professor Alan Calvert
The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers2008
Dr Yvette Drew
Professor Alan Calvert
The potential of PARP inhibitors in genetic breast and ovarian cancers2008
Professor Ruth Plummer
Professor Alan Calvert
[Meeting Abstract] A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI2007
Professor Alan Calvert
Professor John Lunec
A novel monoclonal antibody for detection of folate receptor alpha in paraffin-embedded tissues2007
Professor Ruth Plummer
Rebecca Perrett
Professor Alan Calvert
A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor2007
Professor Alan Calvert
Dr Fathi Azribi
Rebecca Perrett
Professor Ruth Plummer
Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR2007
Dr Michael Cullen
Professor Alan Calvert
Correlation of pemetrexed (PEM) NSCLC exposure-response relationships (ERRS) to clinical study results from western and Japanese patient populations2007
Dr Jo Lee
Dr Mark Verrill
Julieann Sludden
Melanie Griffin
Sharon Erb
et al.
Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer2007
Professor Ruth Plummer
Dr Louise Li
Rebecca Perrett
Professor Alan Calvert
Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers2007
Professor Alan Calvert
Professor Alan Boddy
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: A study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group2007
Professor Ruth Plummer
Professor Alan Calvert
Targeting poly(ADP-ribose) polymerase: A two-armed strategy for cancer therapy2007
Professor Ruth Plummer
Rebecca Perrett
Professor Alan Calvert
A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours2006
Professor Ruth Plummer
Professor Alan Calvert
First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AGO14699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM)2006
Professor Ruth Plummer
Dr Louise Li
Rebecca Perrett
Professor Alan Calvert
Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumours with mutated EGFR2006
Professor Ruth Plummer
Professor Alan Calvert
Phase I study of ispinesib in combination with carboplatin in patients with advanced solid tumors2006
Dr Yan Zhao
Huw Thomas
Michael Batey
Dr Ian Cowell
Professor Roger Griffin
et al.
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU74412006
Professor Ruth Plummer
Rebecca Perrett
Professor Alan Calvert
A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumors2005
Mark Leslie
Julieann Sludden
Professor Ruth Plummer
Dr Alastair Greystoke
Professor Alan Calvert
et al.
A phase I and pharmacodynamic study of a 7 day infusion schedule of the DNMT1 antisense compound MG98.2005
Professor Alan Boddy
Professor Ruth Plummer
Julieann Sludden
Melanie Griffin
Dr Mark Verrill
et al.
A phase I and pharmacokinetic study of paclitaxel poliglumex (XYOTAX), investigating both 3-weekly and 2-weekly schedules2005
Professor Ruth Plummer
Professor Alan Boddy
Professor Nicola Curtin
Professor Herbie Newell
Lynsey Robson
et al.
Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide2005
Professor Ruth Plummer
Dr Christopher Jones
Lynsey Robson
Professor Alan Calvert
First in human phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients (pts) with advanced solid tumors2005
Professor Alan Calvert
Fishing for new drugs2005
Dr Ian Hardcastle
Dr Shafiq Ahmed
Professor Alan Calvert
Professor Nicola Curtin
Gillian Farnie
et al.
Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction2005
Professor Ruth Plummer
Professor Alan Calvert
Phase I and pharmacokinetic study of HGS-ETR2, a fully human agonistic monoclonal antibody to TRAIL-R2, in patients with advanced solid malignancies2005
Professor Alan Calvert
Phase I and pharmacokinetic study of HGS-ETR2, a human monoclonal antibody to TRAIL R2, in patients with advanced solid malignancies.2005
Dr Ashraf Azzabi
Dr Andrew Hughes
Dr Paula Calvert
Professor Ruth Plummer
Melanie Griffin
et al.
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations2005
Dr Graham Dark
Professor Alan Calvert
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: A trial of the national cancer institute of Canada clinical trials group2005
Professor Ruth Plummer
Dr Christopher Jones
Professor Alan Boddy
Professor Alan Calvert
Professor Herbie Newell
et al.
Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-12005
Professor Alan Calvert
Professor Ruth Plummer
The effect of erlotinib on CYP3A4 activity, as quantified by the erythromycin breath test and oral midazolam kinetics in cancer patients: Preliminary results.2005
Professor Alan Calvert
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-895 1f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer2004
Dr Christopher Calabrese
Michael Batey
Professor Alan Calvert
Professor barbara Durkacz
Suzanne Kyle
et al.
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG143612004
Professor Alan Calvert
Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer2004
Dr Christopher Calabrese
Professor Nicola Curtin
Suzanne Kyle
Huw Thomas
Lan Wang
et al.
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase2004
Professor Nicola Curtin
Lan Wang
Suzanne Kyle
Dr Christine Arris
Professor barbara Durkacz
et al.
Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells2004
Professor Alan Calvert
Phase Ib/Il dose-escalation trial evaluating the safety and tolerability of EP0906 plus capecitabine in patients with advanced cancer.2004
Professor Alan Calvert
Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, investigational drug branch for breast cancer and the new drug development group study2004
Professor Nicola Curtin
Hannah Barlow
Professor Alan Calvert
Richard Davison
Professor Bernard Golding
et al.
Resistance-modifying agents. 11. Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to α1-acid glycoprotein2004
Professor Alan Boddy
Gordon Taylor
Dr Andrew Hughes
Professor Alan Calvert
Professor Herbie Newell
et al.
2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG3372003
Professor Ruth Plummer
Dr Andrew Hughes
Dr Martin Highley
Dr Sathyarathna Gokul
Professor Alan Calvert
et al.
A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor2003
Professor Alan Calvert
Cancer drug development in Europe: A selection of new agents under development at the European Drug Development Network2003
Professor Alan Calvert
Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials2003
Tyrone John
Professor Andrew Pearson
Professor Alan Calvert
Dr Michael Tilby
Determination, by ICP-MS, of background and BBR 3464 induced levels of platinum bound to DNA isolated from blood cells: A comparison of the sensitivity of the Perkin Elmer Sciex Elan 6000 and the thermofinnigan Neptune instruments2003
Professor Alan Calvert
Developing drugs for cancer: Striking balance between clinical pragmatism and scientific allure2003
Dr Christopher Calabrese
Michael Batey
Huw Thomas
Professor barbara Durkacz
Lan Wang
et al.
Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies2003
Professor Alan Calvert
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors2003
Professor Alan Calvert
Pemetrexed (Alimta): A promising new agent for the treatment of breast cancer2003
Dr Mark Verrill
Professor Alan Boddy
Julieann Sludden
Kevin Fishwick
Lynsey Robson
et al.
Phase 1 pharmacokinetic (PK) study of CT-2103 given Q2 or Q3 weeks in patients with solid tumors2003
Professor Alan Calvert
Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors2003
Professor Alan Calvert
Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines2003
Tyrone John
Professor Alan Calvert
Dr Michael Tilby
Sensitive determination of BBR 3464 and cisplatin DNA adduct levels in clinical samples using ICP-MS and PIMMS2003
Kerry Louise Sayle
Dr Johanne Bentley
Professor Alan Calvert
Dr YuZhu Cheng
Professor Nicola Curtin
et al.
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 22003
Professor Nicola Curtin
Professor Herbie Newell
Professor Alan Calvert
Professor Roger Griffin
Professor Bernard Golding
et al.
Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors2003
Professor Alan Calvert

Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies

2002
Professor Alan Calvert
A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer2002
Professor Alan Calvert
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial2002
Professor Alan Calvert
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma2002
Professor Alan Calvert
Dr Jane Cassidy
Efficacy, safety, and cost of new anticancer drugs - Pessimistic conclusion was not justified2002
Professor Alan Calvert
Efficacy, safety, and cost of new anticancer drugs; pessimistic conclusion was not justified.2002
Professor Alan Calvert
Folate status and the safety profile of antifolates2002
Professor Alan Calvert
Future directions in the development of pemetrexed2002
Professor Alan Calvert
Homocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy2002
Professor John Lunec
Professor Alan Calvert
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism2002
Dr Christopher Calabrese
Professor Nicola Curtin
Suzanne Kyle
Huw Thomas
Lan Wang
et al.
Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure2002
Professor Alan Calvert
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial2002
Professor Alan Calvert
Patterns of elevation of plasma 2 '-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD93312002
Professor Alan Calvert
Pemetrexed safety and dosing strategy2002
Professor Alan Boddy
Dr Mark Verrill
Julieann Sludden
Kevin Fishwick
Lynsey Robson
et al.
Pharmacological study of CT-2103 (XyotaxTM), a poly(L-glutamic acid)-paclitaxel conjugate administered every 3 weeks or every 2 weeks in a phase I study2002
Professor Ruth Plummer
Dr Paula Calvert
Professor Alan Calvert
Phase I and pharmacokinetic study of the new taxane analog BMS-184476 given weekly in patients with advanced malignancies2002
Dr Andrew Hughes
Dr Paula Calvert
Dr Ashraf Azzabi
Professor Ruth Plummer
Melanie Griffin
et al.
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma2002
Professor Alan Calvert
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types2002
Professor Alan Calvert
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies2002
Michael Batey
Dr Ashraf Azzabi
Professor Herbie Newell
Professor Alan Calvert
Professor Alan Boddy
et al.
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF)2002
Michael Batey
Dr Ashraf Azzabi
Professor Herbie Newell
Professor Alan Calvert
Professor Alan Boddy
et al.
Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) 2002
Huw Thomas
Mike Cole
Suzanne Elliott
Professor Herbie Newell
Professor Alan Calvert
et al.
Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide2002
Dr Andrew Simpson
Dr Paula Calvert
Julieann Sludden
Professor Alan Boddy
Melanie Griffin
et al.
Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules2002
Dr Andrew Hughes
Dr Ashraf Azzabi
Professor Ruth Plummer
Dr Jane Margetts
Kevin Fishwick
et al.
A phase I dose escalation study of doxorubicin in combination with pemetrexed (Alimta (R), multitargeted antifolate).2001
Professor Alan Calvert
A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer2001
Professor Alan Calvert
Activity of the dolastatin analogue, LU103793, in malignant melanoma2001
Professor Nicola Curtin
Dr Stephen Barton
Michael Batey
Dr Christopher Calabrese
Professor Alan Calvert
et al.
Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.2001
Professor Herbie Newell
Professor Alan Calvert
Professor Nicola Curtin
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro2001
Professor Alan Boddy
Dr Martin Highley
Dr John Fenwick
Professor Alan Calvert
Estimation of glomerular filtration rate in cancer patients2001
Peter Smith
Huw Thomas
Hannah Barlow
Professor Roger Griffin
Professor Bernard Golding
et al.
In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity2001
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
Professor Roger Griffin
Dr Ian Hardcastle
et al.
Inhibiting the MDM2-p53 interaction using low molecular weight compounds2001
Professor Alan Boddy
Melanie Griffin
Julieann Sludden
Huw Thomas
Kevin Fishwick
et al.
Pharmacological study of paclitaxel duration of infusion combined with GFR-based carboplatin in the treatment of ovarian cancer2001
Professor Alan Boddy
Dr Mark Verrill
Julieann Sludden
Melanie Griffin
Kevin Fishwick
et al.
Phase I and pharmacological study of CT-2103, a poly(L-glutamic acid)-paclitaxel conjugate2001
Professor Alan Calvert
Randomized double-blind phase II survival study comparing immunization with the anti idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer2001
Professor Martin Noble
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Dr Ashleigh Gibson
et al.
Structural and thermodynamic validation of inactive cdk2 as a template for structure-based drug design2001
Professor Martin Noble
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
et al.
Structure based design of a potent inhibitor of cdk22001
Peter Smith
Huw Thomas
Hannah Barlow
Professor Roger Griffin
Professor Bernard Golding
et al.
In vitro activity and in vivo pharmacology of two novel nucleoside transport inhibitors, NU3108 and NU31212000
Dr Paula Calvert
Dr Ashraf Azzabi
Dr Andrew Hughes
Professor Ruth Plummer
Angela Robinson
et al.
A phase I clinical and pharmacokinetic study of EPO906 (epothilone B) in patients with advanced solid tumours.2000
Professor Alan Calvert
Dr Paula Calvert
Angela Robinson
An intermittent phase I and pharmacokinetic study of BBR3464, a novel cationic triplatinum complex2000
Professor Alan Calvert
Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG)2000
Professor Nicola Curtin
Professor Alan Calvert
Professor barbara Durkacz
Professor Roger Griffin
Professor Bernard Golding
et al.
Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines.2000
Dr Andrew Hughes
Melanie Griffin
Professor Herbie Newell
Professor Alan Calvert
Professor Alan Boddy
et al.
Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, Thymitaq(TM)) and paclitaxel2000
Dr Christopher Calabrese
Professor Nicola Curtin
Michael Batey
Huw Thomas
Suzanne Kyle
et al.
Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase2000
Professor Roger Griffin
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Dr Ashleigh Gibson
et al.
Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors2000
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Dr Ashleigh Gibson
Professor Bernard Golding
et al.
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles2000
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Professor Jane Endicott
Professor Bernard Golding
et al.
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles2000
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
Professor Roger Griffin
et al.
O6-substituted guanines and 4-substituted pyrimidines: a novel class of antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.2000
Professor Alan Boddy
Melanie Griffin
Julieann Sludden
Huw Thomas
Kevin Fishwick
et al.
Paclitaxel and carboplatin dose-intensity and duration of infusion in the treatment of ovarian cancer2000
Huw Thomas
Professor Alan Calvert
Professor Alan Boddy
Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours2000
Dr Paula Calvert
Professor Alan Calvert
Phase II clinical and pharmacokinetic study of exatecan mesylate (DX-8951f) in patients with advanced ovarian cancer, refractory to, or relapsed after platinum and taxane.2000
Lan Wang
Suzanne Kyle
Alex White
Professor Alan Calvert
Professor Nicola Curtin
et al.
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines2000
Professor Roger Griffin
Dr Christine Arris
Dr Christine Bleasdale
Professor Alan Calvert
Professor Nicola Curtin
et al.
Resistance-modifying agents. 8. Inhibition of O6-alkylguanine-DNA alkyltransferase by O6-alkenyl-, O6-cycloalkenyl-, and O6-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O6-(1-cyclopentenylmethyl) guanine2000
Alex White
Professor Alan Calvert
Professor Nicola Curtin
Professor Roger Griffin
Professor Herbie Newell
et al.
Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase2000
Hannah Barlow
Professor Nicola Curtin
Professor Alan Calvert
Professor Bernard Golding
Professor Herbie Newell
et al.
Resistance-modifying agents. Part 7: 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of α1-acid glycoprotein (AGP)2000
Dr Johanne Bentley
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Professor Jane Endicott
et al.
Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors2000
Professor Alan Calvert
Temozolomide and treatment of malignant glioma2000
Professor Roger Griffin
Hannah Barlow
Professor Nicola Curtin
Professor Alan Calvert
Professor Bernard Golding
et al.
2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha(1)-acid glycoprotein (AGP)1999
Dr Andrew Hughes
Professor Alan Calvert
An update on thymidylate synthase inhibitors1999
Professor Herbie Newell
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Dr Ashleigh Gibson
et al.
Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.1999
Dr Brian Angus
Dr Sathyarathna Gokul
Professor Alan Calvert
Professor John Lunec
Bcl-2 expression is a potential prognostic co-factor with P53- mutation status in epithelial ovarian carcinoma1999
Professor Alan Calvert
Dr Martin Highley
Professor John Lunec
Professor Alan Boddy
Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene1999
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Dr Ashleigh Gibson
Professor Bernard Golding
et al.
In vitro growth activity of novel purine- and pyrimidine-based CDK1 and CDK2 inhibitors.1999
Peter Smith
Professor Alan Calvert
Professor Herbie Newell
Professor Nicola Curtin
MTA (LY231514) induced intracellular dNTP pool pertubations are alleviated by salvage of pre-formed purines and pyrimidines1999
Professor Alan Calvert
MTA, a novel multitargeted antifolate, from preclinical to phase I and beyond: summary and conclusions1999
Peter Smith
Hannah Barlow
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
et al.
Novel dipyridamole analogues potentiate the in vitro activity of MTA (LY231514) in the presence of alpha(1)-acid glycoprotein.1999
Dr Michael Tilby
Professor Alan Calvert
Professor Herbie Newell
Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: Effect on drug-plasma AUC and peripheral blood drug-DNA adduct levels1999
Dr Andrew Hughes
Melanie Griffin
Professor Alan Calvert
Professor Herbie Newell
Professor Alan Boddy
et al.
Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days1999
Professor Ruth Plummer
Professor Alan Calvert
Dr Martin Highley
Phase I trial of ZD9331 in adult patients with refractory solid malignancies administered by 30-min infusion on days 1 and 8 with the cycle repeated every 3 weeks1999
Professor Alan Calvert
Phase II study results on safety and efficacy of CAELYX®(DOXIL®) in combination with paclitaxel in the treatment of metastatic breast cancer1999
Michael Batey
Kevin Fishwick
Dr Ashraf Azzabi
Professor Herbie Newell
Professor Alan Calvert
et al.
Population pharmacokinetics of CMF in the adjuvant treatment of breast cancer1999
Professor Nicola Curtin
Professor Alan Calvert
Professor barbara Durkacz
Professor Herbie Newell
Potentiation of temozolomide and topotecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines.1999
Professor Nicola Curtin
Suzanne Kyle
Lan Wang
Professor barbara Durkacz
Professor Roger Griffin
et al.
Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors1999
Professor Nicola Curtin
Professor Alan Calvert
Professor Bernard Golding
Professor Roger Griffin
Professor Herbie Newell
et al.
Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced α1-acid glycoprotein binding1999
Dr Christopher Calabrese
Huw Thomas
Michael Batey
Professor Nicola Curtin
Professor Roger Griffin
et al.
Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase1999
Peter Smith
Professor Alan Calvert
Professor Herbie Newell
Professor Nicola Curtin
Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines1999
Dr John Lunn
Professor Steve Wedge
Professor Herbie Newell
Professor Alan Calvert
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma1998
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
Professor Roger Griffin
Professor Herbie Newell
et al.
2-phenylbenzimidazole-4-carboxamides are potent inhibitors of the DNA repair enzyme poly(ADP-ribose)-polymerase (PARP)1998
Professor Herbie Newell
Professor Alan Calvert
Professor Anne Dickinson
Professor Frederick Campbell
Professor Nicola Curtin
et al.
Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro1998
Professor Alan Calvert
Professor Herbie Newell
Professor Nicola Curtin
Dipyridamole selectively potentiates antipurine antifolates in human tumour cell lines but not normal tissue targets of dose-limiting toxicity1998
Professor Jane Endicott
Professor Martin Noble
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
et al.
Insights into CDK inhibitor design from X-ray crystallographic studies1998
Professor Alan Calvert
Professor Nicola Curtin
Professor Jane Endicott
Professor Bernard Golding
Professor Roger Griffin
et al.
O-6-alkylguanines as selective inhibitors of cyclin dependent kinases1998
Dr Andrew Hughes
Melanie Griffin
Professor Alan Calvert
Andrew Johnston
Professor Herbie Newell
et al.
Pharmacokinetic interactions in a phase I study of nolatrexed (AG337, THYMITAQ TM) and paclitaxel in patients with advanced solid tumours1998
Peter Smith
Professor Herbie Newell
Professor Alan Calvert
Professor Nicola Curtin
Potentiation of the in vitro activity of the multi-targeted antifolate MTA (LY231514) by dipyridamole1998
Professor Alan Boddy
Gordon Taylor
Professor Herbie Newell
Professor Alan Calvert
Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given prolonged administration in patients with solid tumors1998
Professor Roger Griffin
Professor Alan Calvert
Professor Nicola Curtin
Professor Herbie Newell
Professor Bernard Golding
et al.
Resistance-modifying agents. 5.1 Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)1998
Professor Alan Boddy
Huw Thomas
Lynsey Robson
Professor Alan Calvert
A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer1997
Professor Alan Calvert
Good manners for the pharmaceutical industry1997
Professor Alan Calvert
Dr Andrew Hall
Professor John Lunec
Professor Herbie Newell
Professor Andrew Pearson
et al.
The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQ® in human leukaemia and colorectal carcinoma cell lines1997
Professor Steve Wedge
Fiona Chapman
Gordon Taylor
Huw Thomas
Professor Alan Boddy
et al.
A phase I clinical study of the antipurine antifolate lometrexol (DDATHF) given with oral folic acid1996
Professor Alan Calvert
Professor Herbie Newell
A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve1996
Professor Alan Calvert
Dr John Anderson
Professor David Neal
Professor John Lunec
Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer1996
Professor Herbie Newell
Huw Thomas
Professor Alan Calvert
Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters1996
Professor Alan Boddy
Huw Thomas
Professor Herbie Newell
Professor Alan Calvert
Lynsey Robson
et al.
Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: A cancer research campaign phase I/II committee study1996
Dr Christine Arris
Dr Christine Bleasdale
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
et al.
Mechanism-based inhibition of O-6-methylguanine-DNA methyltransferase.1996
Professor Roger Griffin
Alex White
Kenneth Bowman
Professor Alan Calvert
Professor Nicola Curtin
et al.
Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme Poly(ADP-ribose)polymerase1996
Kevin Fishwick
Lynsey Robson
Professor Alan Calvert
Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer1996
Dr Andrew Hall
Professor Alan Calvert
Dr James Sunter
Professor Herbie Newell
The relationship between tumour glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients1996
Professor Farhad Kamali
Russell Wallace
Professor Alan Calvert
The safety of sumatriptan administration 2 h after subcutaneous injection of alniditan, a new anti-migraine drug, in healthy volunteers1996
Professor Alan Calvert
Cancer-research campaign phase-II trail of temozolomide in metastatic melanoma1995
Professor Alan Calvert
Professor Alan Boddy
Dr Andrew Hughes
Lynsey Robson
Huw Thomas
et al.
Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions.1995
Gordon Taylor
Professor Alan Boddy
Professor Alan Calvert
Andrew Johnston
Professor Herbie Newell
et al.
Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridplthio)-quinazolone dihydrochloride (AG337) given by 24-hour continuous intravenous infusion1995
Professor Steve Wedge
Gordon Taylor
Professor Alan Boddy
Professor Alan Calvert
Professor Herbie Newell
et al.
Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement1995
Professor Alan Calvert
Professor John Lunec
Molecular characterisation of 2 cell-lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD16941995
Lynsey Robson
Professor Alan Calvert
Oral folic acid improves lometrexol toxicity profile: A phase I study1995
Professor Herbie Newell
Professor Alan Calvert
Pharmacokinetics and Pharmacodynamics of Prolonged Oral Etoposide in Women with Metastatic Breast-Cancer1995
Professor Herbie Newell
Gordon Taylor
Professor Alan Calvert
Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481)1995
Professor Alan Calvert
Quinazoline antifolate thymidylate synthase inhibitors: replacement of glutamic acid in the C2-methyl series1995
Professor Alan Calvert
Role of Taxanes in Cancer-Therapy1995
Professor Roger Griffin
Professor Nicola Curtin
Professor Herbie Newell
Professor Bernard Golding
Professor barbara Durkacz
et al.
The Role of Inhibitors of Poly(Adp-Ribose) Polymerase as Resistance-Modifying Agents in Cancer-Therapy1995
Professor Alan Calvert
The use of granulocyte-colony-stimulating factor to deliver 4 cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast-cancer1995
Professor Alan Calvert
A Cancer-Research Campaign (Crc) Phase-Ii Trial of Cb10-277 Given by 24-Hour Infusion for Malignant-Melanoma1994
Professor Alan Calvert
A Dose-Finding Study of Granisetron, a Novel Antiemetic, in Patients Receiving High-Dose Cisplatin1994
Professor Alan Calvert
A strategy for the design of membrane-permeable folylpoly- gamma-glutamate synthetase inhibitors - bay-region-substituted 2-desamino-2-methyl-5,8-dideazafolate analogs1994
Professor Alan Calvert
Carboplatin and granulocyte-colony-stimulating factor as first-line treatment for epithelial ovarian-cancer - a phase-I dose-intensity escalation study1994
Professor Alan Calvert
Dose optimization of carboplatin in adults1994
Dr Christine Arris
Dr Christine Bleasdale
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
et al.
Probing the active site and mechanism of action of O-6-methylguanine-DNA methyltransferase with substrate-analogs to (O-6-substituted guanines)1994
Professor Alan Calvert
The Synthesis and Thymidylate Synthase Inhibitory Activity of L-Gamma-L-Linked Dipeptide and L-Gamma-Amide Analogs of 2- Desamino-2-Methyl-N(10)-Propargyl-5,8-Dideazafolic Acid (Ici- 198583)1994
Professor Alan Calvert
Advanced epithelial ovarian-cancer - 1993 Consensus Statements1993
Professor Herbie Newell
Professor Andrew Pearson
Dr Michael Keir
Professor Alan Calvert
Carboplatin Pharmacokinetics in Children - the Development of a Pediatric Dosing Formula1993
Professor Alan Calvert
Emeritus Professor Nick Europe-Finner
Comparison of myelotoxicity relating to 2 chemotherapy regimens for small-cell lung-cancer (SCLC)1993
Professor Alan Calvert
Gamma-linked dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid as antitumour agents1993
Professor Alan Calvert
Angela Robinson
Professor Herbie Newell
Long-Term Oral Etoposide in Metastatic Breast-Cancer - Clinical and Pharmacokinetic Results1993
Professor Herbie Newell
Professor Alan Calvert
Phase-I trial with pharmacokinetics of Cb10-277 given by 24 hours continuous infusion1993
Professor Alan Calvert
Platinum Complexes in Cancer Medicine - Pharmacokinetics and Pharmacodynamics in Relation to Toxicity and Therapeutic Activity1993
Professor Herbie Newell
Professor Alan Calvert
Preclinical, Phase-I and Pharmacokinetic Studies with the Dimethyl Phenyltriazene-Cb10-2771993
Professor Herbie Newell
Professor Alan Calvert
Clinical Pharmacokinetics of the Anthrapyrazole Ci-941 - Factors Compromising the Implementation of a Pharmacokinetically Guided Dose Escalation Scheme1992
Professor Alan Calvert
Professor Herbie Newell
Future directions with carboplatin: Can Therapeutic Monitoring, High-Dose Administration, and Hematologic Support with Growth Factors Expand the Spectrum Compared with Cisplatin?1992
Professor John Lunec
Professor Alan Calvert
Human Lymphoblastoid-Cells with Acquired-Resistance to C2- Desamino-C2-Methyl-N10-Propargyl-5,8-Dideazafolic Acid - a Novel Folate-Based Thymidylate Synthase Inhibitor1992
Professor Herbie Newell
Professor Alan Calvert
Phase-I Trial of the Anthrapyrazole Ci-941 - Prospective Evaluation of a Pharmacokinetically Guided Dose-Escalation1992
Professor Alan Calvert
Quinazoline antifolate thymidylate synthase inhibitors: difluoro-substituted benzene ring analogs1992
Professor Alan Calvert
Structural basis for recognition of polyglutamyl folates by thymidylate synthase1992
Professor Alan Calvert
Syntheses and Thymidylate Synthase Inhibitory Activity of the Poly-Gamma-Glutamyl Conjugates of N- 5- N-(3,4-Dihydro-2- Methyl-4-Oxoquinazolin-6-Ylmethyl)-N-Methylamino -2-Thenoyl -L- Glutamic Acid (Ici D1694) and Other Quinazoline Antifolates1992
Professor Alan Calvert
Anthrapyrazole CI941 - a highly-active new agent in the treatment of advanced breast cancer1991
Professor Alan Calvert
Combining cisplatin and carboplatin complementary or contradictory1991
Geoffrey Taylor
Professor Alan Calvert
ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study1991
Professor Alan Calvert
Phase-II trial of trimelamol in refractory ovarian cancer1991
Professor Alan Calvert
Quinazoline antifolate thymidylate synthase inhibitors: bridge modifications and conformationally restricted analogs in the C2-methyl series1991
Professor Alan Calvert
Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications1991
Professor Alan Calvert
Quinazoline antifolates inhibiting thymidylate synthase - 4- thio-substituted analogs1991
Professor Herbie Newell
Geoffrey Taylor
Professor Alan Calvert
The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583)1991
Professor Alan Calvert
The Costs of Carboplatin Treatment1991
Professor Herbie Newell
Professor Alan Calvert
The pharmacokinetics of the quinazoline antifolate ICI D 1694 in mice and rats1991
Professor Herbie Newell
Sarah Morgan
Professor Alan Calvert
The renal effects of N-10-propargyl-5,8-dideazafolic acid (CB 3717) and a non-nephrotoxic analog ICI D 1694, in mice1991
Professor Alan Calvert
Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2- methyl-N10-substitted-5,8-dideazafolates1991
Professor Alan Calvert
21-day cycles of oral etoposide in heavily pretreated metastatic germ-cell cancer1990
Geoffrey Taylor
Professor Alan Calvert
Activity of the thymidylate synthase inhibitor 2-desamino-N-10- propargyl-5,8-dideazafolic acid and related-compounds in murine (L1210) and human (W1l2) systems in Vitro and in L1210 in Vivo1990
Professor Alan Calvert
Quinazoline antifolate thymidylate synthase inhibitors - 2'- fluoro-N-10-propargyl-5,8-dideazafolic acid and derivatives with modifications in the C-2 position1990
Professor Alan Calvert
Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C-2 position1990
Professor Alan Calvert
Quinazoline antifolate thymidylate synthase inhibitors: benzoyl ring modifications in the C2-methyl series1990
Professor Alan Calvert
Recent advances in cancer-chemotherapy1990
Professor Herbie Newell
Professor Alan Calvert
Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma1989
Professor Alan Calvert
Professor Herbie Newell
Carboplatin Dosage - Prospective Evaluation of a Simple Formula Based on Renal-Function1989
Professor Alan Calvert
Cisplatin Carboplatin Cross-Resistance in Ovarian-Cancer1989
Professor Herbie Newell
Professor Alan Calvert
Determination of the Anthrapyrazole Anticancer Drug Ci-941 in Plasma and Urine by Solid-Phase Extraction and High-Performance Liquid-Chromatography1989
Geoffrey Taylor
Professor Alan Calvert
Estimation of the in vitro and in vivo inhibitory effects of antifolates upon thymidylate synthase (TS) in whole cells1989
Professor Alan Calvert
Introduction - a history of the progress of anticancer chemotherapy1989
Professor Alan Calvert
Phase-I trial and pharmacokinetics of trimelamol (N2,N4,N6- trihydroxymethyl-N2,N4,N6-trimethylmelamine)1989
Professor Herbie Newell
Professor Alan Calvert
Preclinical and Clinical Pharmacokinetic Studies with 1-(4-Carboxyphenyl)-3, 3-Dimethyl Triazene (CB10-277)1989
Professor Alan Calvert
Quinazoline antifolate thymidylate synthase inhibitors: nitrogen, oxygen, sulfur, and chlorine substituents in the C2 position1989
Professor Alan Calvert
Quinazoline antifolates inhibiting thymidylate synthase - computer modeling of the N-10 substituent1989
Professor Herbie Newell
Professor Alan Calvert
Quinazoline antifolates inhibiting thymidylate synthase: 2- desamino derivatives with enhanced solubility and potency1989
Professor Herbie Newell
Professor Alan Calvert
The pharmacokinetics and toxicity of the anthrapyrazole anti- cancer drug Ci-941 in the mouse - a guide for rational dose escalation in patients1989
Professor Herbie Newell
Gordon Taylor
Professor Alan Calvert
Thymidylate synthase - a target for anticancer drug design1989
Professor Alan Calvert
Carboplatin or cisplatin1988
Professor Herbie Newell
Professor Alan Calvert
Development of an assay for the estimation of N10-propargyl- 5,8-dideazafolic acid polyglutamates in tumor cells1988
Professor Herbie Newell
Professor Alan Calvert
Formation and retention and biological activity of N10- propargyl-5,8-dideazafolic acid (CB 3717) polyglutamates in L1210 cells in vitro1988
Professor Alan Calvert
Phase-II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB3717) in advanced breast-cancer1988
Professor Alan Calvert
A Phase II study of Carboplatin in metastatic transitional cell carcinoma of the bladder1987
Professor Alan Calvert
High dose carboplatin in the treatment of lung-cancer and mesothelioma: a phase I dose escalation study1987
Professor Herbie Newell
Professor Alan Calvert
Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin1987
Professor Alan Calvert
Professor Herbie Newell
Recent preclinical and clinical studies with the thymidylate synthase inhibitor N10-propargyl-5,8-dideazafolic acid (CB3717)1987
Professor Herbie Newell
Professor Alan Calvert
Tumor necrosis factor in man - clinical and biological observations1987
Professor Alan Calvert
Professor Herbie Newell
A Phase-I Evaluation of the Quinazoline Antifolate Thymidylate Synthase Inhibitor, N-10-Propargyl-5,8-Dideazafolic Acid, Cb37171986
Professor Alan Calvert
Increased Thymidylate Synthase in L1210 Cells Possessing Acquired-Resistance to N10-Propargyl-5,8-Dideazafolic Acid (CB 3717) - Development, Characterization, and Cross-Resistance Studies1986
Professor Herbie Newell
Professor Alan Calvert
Pharmacokinetics of the thymidylate synthase inhibitor N10- propargyl-5,8-dideazafolic acid (CB 3717) in the mouse1986
Professor Alan Calvert
Phase-II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma1986
Professor Alan Calvert
Phase-II trials in metastatic bladder-cancer1986
Professor Alan Calvert
Quinazoline antifolates inhibiting thymidylate synthase: benzoyl ring modifications1986
Professor Alan Calvert
Quinazoline antifolates inhibiting thymidylate synthase: variation of the amino-acid1986
Professor Herbie Newell
Professor Alan Calvert
The effect of the nucleoside transport inhibitor dipyridamole on the incorporation of H3 thymidine in the rat1986
Professor Alan Calvert
Carboplatin - a very active new cisplatin analog in the treatment of small cell lung cancer1985
Professor Alan Calvert
Professor Herbie Newell
Phase-I Studies with Carboplatin at the Royal-Marsden-Hospital1985
Professor Alan Calvert
Professor Herbie Newell
Quinazoline antifolates inhibiting thymidylate synthase: variation of the N-10 substituent1985
Professor Herbie Newell
Professor Alan Calvert
The clinical pharmacokinetics of the novel antifolate N10- propargyl-5,8-dideazafolic acid (CB 3717)1985
Professor Alan Calvert
Inhibition of thymidylate synthetase by the new quinazoline antifolate, CB 3717: enzyme purification and Kinetics1984
Geoffrey Taylor
Professor Alan Calvert
Modulation of anti-metabolite effects: effects of thymidine on the efficacy of the quinazoline based thymidylate synthetase inhibitor, CB37171984
Professor Herbie Newell
Professor Alan Calvert
Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function1984
Geoffrey Taylor
Professor Alan Calvert
Plasma nucleoside and base levels following treatment with the new thymidylate synthetase inhibitor-CB-37171984
Professor Alan Calvert
Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, N-(4-(N-((2-amino-4-hydroxy-6- quinazolinyl)methyl)prop-2-ynylamino)benzoyl)-L-glutamic acid (Cb3717), on human-lymphoblastoid cells1983
Professor Alan Calvert
Phase-II study of JM8, a new platinum analog, in advanced ovarian-carcinoma1983
Professor Herbie Newell
Professor Alan Calvert
Studies on the pharmacokinetics of chlorambucil and prednimustine in man1983
Professor Alan Calvert
Professor Herbie Newell
Early Clinical-Studies with Cis-Diammine-1,1-Cyclobutane Dicarboxylate Platinum-Ii1982
Professor Alan Calvert
A potent anti tumor quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice1981
Geoffrey Taylor
Professor Alan Calvert
Methotrexate with thymidine, inosine, and allopurinol rescue - a phase-I clinical-study1981
Professor Alan Calvert
Gordon Taylor
Quinazoline antifolates with dual biochemical loci of action. Biochemical and Biological studies directed towards overcoming methotrexate resistance1980
Professor Alan Calvert
Gordon Taylor
The intracellular mechanism of action of metoprine (DDMP)1980
Professor Alan Calvert
A randomised combination chemotherapy trial with and without adriamycin in squamous cell carcinoma of the head and neck1978
Professor Alan Calvert
Improved results in combination chemotherapy of head and neck cancer using a kinetically based approach: a randomised study with and without adriamycin1978
Professor Alan Calvert
Intrathoracic lymphoma associated with atrial arrhythmias and atrioventricular conduction defects1978
Professor Alan Calvert
An enzyme inhibition assay for 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (DDMP)1977
Professor Alan Calvert
Some observations on the human pharmacology of methotrexate1977
Professor Alan Calvert
A kinetically based multiple drug treatment for cancer of the head and neck1975
Professor Alan Calvert
Mortality in protein calorie malnutrition1972